Rituximab for the treatment of the skin manifestations of dermatomyositis: A report of 3 cases
Hope V Dinh, Christopher McCormack, Stephen Hall, H Miles Prince
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | MOSBY-ELSEVIER | Published : 2007
Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent recalcitrant skin manifestations are described. All patients demonstrated good control of muscle symptoms on immunosuppressive medications, but their cutaneous disease persisted despite treatment with at least 4 different systemic treatments and topical agents. They were given rituximab, a monoclonal anti-CD20 antibody, achieving a response with minimal side effects. We document our experience with this medication for the cutaneous lesions of dermatomyositis.